Comment on CMS-2026-1256-0002

Summary: Abbott, a medical technology and nutrition manufacturer, opposes the proposed repeal of the alternative NTAP and OPPS device pass-through payment pathways for FDA-designated Breakthrough Devices. They argue that these pathways are essential for fostering innovation, ensuring timely patient access to transformative technologies, and recognizing the rigorous clinical standards already established by the FDA.